Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019116
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.91
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer89
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification80
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer76
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes69
Clinical assays for assessment of homologous recombination DNA repair deficiency68
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer61
Uterine serous carcinoma60
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer58
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment57
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes56
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study56
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity56
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses55
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers54
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival52
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial52
Gynecologic cancer in pregnancy51
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer49
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial49
Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study48
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations48
Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial48
Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer47
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma45
Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?45
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study45
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study45
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study44
Harnessing natural killer cells for the treatment of ovarian cancer44
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis43
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract43
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial43
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study42
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss42
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer41
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer41
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial41
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer39
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic39
Immunotherapy for platinum-resistant ovarian cancer39
Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma39
0.040167093276978